Pfizer vs. Bristol Myers Squibb: Which Is the Superior Dividend Stock?
Yahoo Finance ·
Pharmaceutical giants Pfizer and Bristol Myers Squibb share several traits, including facing upcoming patent cliffs and posting double-digit stock gains this year. Both are favorites among income-focused investors, but choosing the better long-term holding requires a closer look at their payout metrics. Pfizer boasts a high forward dividend yield of 5.8%, placing it near the top of the S&P 500. However, its recent GAAP payout ratio has exceeded 100 percent. Conversely, Bristol Myers Squibb provides a solid yield of around 4.3 percent while boasting a remarkable track record of 94 consecutive years of payments and 17 straight years of increases. Furthermore, Bristol maintains a much safer payout ratio of approximately 55 percent of its earnings, making it a reliable option for dividend stability.
AI 시장 분석
Pfizer and Bristol Myers Squibb, representing high-dividend stocks in the pharmaceutical industry, have achieved double-digit stock price gains this year. Pfizer recorded a high dividend yield of 5.8%, ranking near the top of the S&P 500, but faces the burden of a GAAP payout ratio exceeding 100%. Conversely, Bristol Myers Squibb shows a 4.3% yield with 17 consecutive years of increases and a stable payout ratio of around 55%. Investors must carefully evaluate the balance between dividend sustainability and financial health.
상승 영향
- Biotechnology — Both Pfizer and Bristol Myers Squibb offer attractive dividend yields (5.8% and 4.3%, respectively), continuously driving income investment demand.
하락 영향
- Biotechnology — Pfizer's payout ratio exceeds 100%, raising financial burdens and dividend stability concerns, alongside patent expiration risks across pharmaceutical companies.
DYAX 전담 분석
Amid the patent expiration crisis facing major pharmaceutical companies, Pfizer and Bristol Myers Squibb are attracting income investors with their high-dividend appeal. While Pfizer's high yield of 5.8% is attractive, financial pressure and concerns over dividend cuts persist due to a payout ratio exceeding 100%. In contrast, Bristol Myers Squibb demonstrates solid cash flow with a stable payout ratio of 55% and a 17-year streak of dividend increases.
In the bullish scenario, successful commercialization of new drug pipelines could improve cash generation capabilities, highlighting dividend stability. In the bearish scenario, sharp revenue declines due to patent expirations and financial deterioration from high payout ratios could lead to stock price declines and dividend reduction risks. Key indicators to watch include GAAP and Non-GAAP payout ratios and quarterly earnings growth.
AI가 생성한 분석으로 투자 자문이 아닙니다.
DYAX Investor Sentiment
Bullish (Long) 56% · Bearish (Short) 44%
505 participants
Related News
- Warren Buffett's Advice for Investors Facing Potential Market Volatility
- McDonald's Stock Down 20% in 2026: Is It Time to Buy?
- BlackRock CEO Larry Fink Suggests U.S. Retirement Savings Should Fund $10 Trillion AI Infrastructure
- Autoliv Shares Drop Following Third-Quarter Earnings Release
- Infosys Reports Q2 2026 Results and Lowers FY27 Revenue Outlook
- Apple Nears Nvidia to Reclaim Crown as World's Most Valuable Company
